Provided by Tiger Trade Technology Pte. Ltd.

CytomX Therapeutics

4.52
+0.10002.26%
Post-market: 4.520.00000.00%19:49 EDT
Volume:7.54M
Turnover:34.39M
Market Cap:977.12M
PE:-30.13
High:4.80
Open:4.40
Low:4.37
Close:4.42
52wk High:8.21
52wk Low:0.4000
Shares:216.18M
Float Shares:113.00M
Volume Ratio:1.14
T/O Rate:6.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1500
EPS(LYR):-0.1500
ROE:-35.25%
ROA:-8.99%
PB:9.87
PE(LYR):-30.13

Loading ...

Earnings Flash (CTMX) CytomX Therapeutics Posts 2025 Loss $0.15 a Share, vs. FactSet Est of $0.03 Loss

MT Newswires Live
·
Mar 16

CytomX Therapeutics Inc - Phase 1 Study With Bevacizumab Initiated; Phase 1B/2 Chemotherapy Combination Study to Start by End 2026

THOMSON REUTERS
·
Mar 16

CytomX’s Varsetatug Masetecan (Epcam Probody® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

THOMSON REUTERS
·
Mar 16

CytomX Therapeutics Q4 EPS $(0.22) Misses $(0.09) Estimate, Sales $663.000K Miss $7.900M Estimate

Benzinga
·
Mar 16

BRIEF-CytomX Therapeutics FY Revenue USD 76.201 Million Vs. IBES Estimate USD 83.5 Million

Reuters
·
Mar 16

CytomX reports FY2025 revenue of USD 76.2 million and cash of USD 137.1 million

Reuters
·
Mar 16

CytomX Therapeutics FY Net Income USD -17.368 Million

THOMSON REUTERS
·
Mar 16

CytomX reports 32% ORR for varsetatug masetecan in Phase 1 late-line metastatic colorectal cancer study

Reuters
·
Mar 16

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 16

U.S. Earnings Preview: Before Market Open March 16

Dow Jones
·
Mar 16

CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga
·
Mar 16

Wedbush Remains a Buy on CytomX Therapeutics (CTMX)

TIPRANKS
·
Mar 16

Top News Today/Canada: Unemployment Rate Rises to 6.7%

Dow Jones
·
Mar 14

CytomX Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
Mar 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 13

CytomX Therapeutics Price Target Maintained With a $10.00/Share by Guggenheim

Dow Jones
·
Mar 09

CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

GlobeNewswire
·
Mar 04

CytomX Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
Mar 02

CytomX Therapeutics (CTMX) Receives a Buy from Barclays

TIPRANKS
·
Feb 17

CytomX Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Feb 04